Clinical Trial Update: ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ACALA-R in predominantly demyelinating IgM-mediated neuropathy; the study involves IgM monoclonal gammopathy of undetermined s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igm Monoclonal Gammopathy of Undetermined Significance
• Peripheral Neuropathy
• Waldenström Macroglobulinemia

Drugs mentioned

• ACALA-R

Snippet

Sponsor: Shayna Sarosiek, MD | Conditions: IgM MGUS, Waldenstrom Macroglobulinemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING